Amgen, Inc. is continuing down its chosen 2021 path of M&A, entering into an agreement to acquire the private US venture Teneobio, Inc. for $900m in cash upfront, plus future contingent milestone payments worth up to an additional $1.6bn in cash, in a bid to build out multiple technologies in the antibody space.
Amgen Builds Out Antibody Interests With $2.5bn Teneobio Buy
$900m Upfront
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.
